Detail akcie Iterum Therap Rg online

Business Summary: Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Iterum Therapeutics PLC revenues increased from $0K to $390K. Net loss increased 12% to $20.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Drug Resistant Bacterial Infection segment loss increase of 91% to $17M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.06 to -$0.50.